SELLAS Life Sciences Group, Inc.
SLS
$12.78
$0.423.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.83% | 44.26% | -32.28% | -3.37% | 23.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.10% | 52.60% | -10.76% | -3.36% | -9.81% |
| Operating Income | -40.10% | -52.60% | 10.76% | 3.36% | 9.81% |
| Income Before Tax | -45.51% | -44.62% | -13.67% | 4.46% | 11.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.51% | -44.62% | -13.67% | 4.46% | 11.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.51% | -44.62% | -13.67% | 4.46% | 11.63% |
| EBIT | -40.10% | -52.60% | 10.76% | 3.36% | 9.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 24.18% | 26.44% | 40.50% | 39.87% | 48.30% |
| Normalized Basic EPS | 32.22% | 26.33% | 56.19% | 39.78% | 48.27% |
| EPS Diluted | 24.18% | 26.44% | 40.50% | 39.87% | 48.46% |
| Normalized Diluted EPS | 32.22% | 26.33% | 56.19% | 39.78% | 48.27% |
| Average Basic Shares Outstanding | 91.95% | 96.54% | 90.93% | 58.81% | 71.02% |
| Average Diluted Shares Outstanding | 91.95% | 96.54% | 90.93% | 58.81% | 71.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |